April Journal-2009.p65 - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 3 (2) 181-187, April 2009. ISSN 0973-8916
186
the major genetic determinant of
polymorphic activity in humans.
Pharmacogenetics, 10: 415-424.
Fig. 1: Electrophoretogram of Dde I digested
PCR product generated by amplification of
genomic DNA using CYP3A5*3 gene
specific primers.
Lane # 1: 100 bp DNA ladder
lane # 2: 3/3Genotype
lane # 3,: 1/3Genotype
lane # 4: 1/1Genotype
Fig. 2: Electrophoretogram of Dde I digested
PCR product generated by amplification of
genomic DNA using CYP3A5*6 gene
specific primers.
Lane # 1-4: 1/1
lane # 5: Uncut band
lane # 6,: 100 bp DNA ladder
Reference
1. Paulussen A., Lavrijsen K., Bohets H.,
Hendrickx J., Verhasselt P., Luyten W.,
Konings F. and Armstrong M. (2000). Two
linked mutations in transcriptional regulatory
elements of the CYP3A5 gene constitute
2. Gellner K., Eiselt R., Hustert E., Arnold H.,
Koch I., Haberl M., Deglmann CJ., Burk
O., Buntefuss D., Escher S., Bishop C.,
Koebe HG., Brinkmann U., Klenk HP.,
Kleine K., Meyer UA. and Wojnowski L.
(2001). Genomic organization of the human
CYP3A locus: identification of a new,
inducible CYP3A gene. Pharmacogenetics,
11: 111-121.
3. Jounaidi Y., Guzelian PS., Maurel P. and
Vilarem MJ. (1994). Sequence of the 5-
prime-flanking region of CYP3A5:
comparative analysis with CYP3A4 and
CYP3A7. Biochem. Biophys Res Commun,
205: 1741-1747.
4. Kuehl P., Zhang J., Lin Y., Lamba J., Assem
M., Schuetz J., Watkins PB., Daly A.,
Wrighton SA., Hall SD., Maurel P., Relling
M., Brimer C., Yasuda K., Venkataramanan
R., Strom S., Thummel K., Boguski MS.
and Schuetz E. (2001). Sequence diversity
in CYP3A promoters and characterization
of the genetic basis of polymorphic
CYP3A5 expression. Nature Gene, 27: 383-
391.
5. Park SY., Kang YS., Jeong MS., Yoon
HK. and Han KO. (2008). Frequencies
of CYP3A5 genotypes and haplotypes in
a Korean population. Pharmacogenetics,
33 (1): 61-65.
6. Liu TC., Lin SF., Chen TP. and Chang JG.
(2001). Polymorphism analysis of CYP3A5
in myeloid leukemia. Oncol Rep,9(2):327-
9.
7. Nuremberg JI. and Lahari D KJr. (1991).
A rapid non-enzymatic method for the
Surekha et al